Prevention & lipidsCohort study
Interplay of HDL cholesterol and Apolipoprotein B (apoB) and the risk of incident atherosclerotic cardiovascular disease in UK Biobank
- Prospective cohort study
Authors' conclusion
High HDL-C is associated with lower ASCVD risk, independent of apoB, and it attenuates the effect of high apoB on ASCVD risk.
Study context
- Population
- UK Biobank participants aged 37–73, free of CVD, not on lipid-lowering medication
- Participants
- 293,872 participants
- Exposure
- HDL-C and apoB as mutually adjusted exposures
- Outcome
- Incident ASCVD
- Follow-up
- 10 years
Main finding
As reported in the abstract
Incident ASCVD, per 1 SD (adjusted for standard risk factors incl. log-TG)
Hazard ratio (95% CI)P value
apoB (model with HDL-C residual)
1.16(1.15–1.18)
P < 0.001HDL-C residual (model with apoB)
0.85(0.84–0.87)
P < 0.001apoB residual (model with HDL-C)
1.14(1.12–1.16)
P < 0.001HDL-C (model with apoB residual)
0.84(0.82–0.85)
P < 0.001Per 1 SD, as printed
Observational data: associations, not effects.
Further findings
apoB–HDL-C interaction on incident atherosclerotic cardiovascular disease (ASCVD)
| Comparison | HR (95% CI) | P value | |
|---|---|---|---|
| apoB × HDL-C interaction · consistent across sexes | 0.95 (0.93–0.96) | P < 0.001 | |
| 0.512Hazard ratio (log scale) |
Original publication
Interplay of HDL cholesterol and apoB and the risk of incident atherosclerotic cardiovascular disease in UK Biobank. Eur J Prev Cardiol. Published 31 July 2026. doi:10.1093/eurjpc/zwag400
Summarised from the published abstract; every number is checked against it